MXPA04010474A - Piperazinbenzotiazoles como agentes para el tratamiento de trastornos isquemicos cerebrales o trastornos del sistema nerviosos central. - Google Patents

Piperazinbenzotiazoles como agentes para el tratamiento de trastornos isquemicos cerebrales o trastornos del sistema nerviosos central.

Info

Publication number
MXPA04010474A
MXPA04010474A MXPA04010474A MXPA04010474A MXPA04010474A MX PA04010474 A MXPA04010474 A MX PA04010474A MX PA04010474 A MXPA04010474 A MX PA04010474A MX PA04010474 A MXPA04010474 A MX PA04010474A MX PA04010474 A MXPA04010474 A MX PA04010474A
Authority
MX
Mexico
Prior art keywords
piperazin
pyrimidin
benzothiazol
methyl
benzyl
Prior art date
Application number
MXPA04010474A
Other languages
English (en)
Spanish (es)
Inventor
Jean-Pierre Gotteland
Original Assignee
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems filed Critical Applied Research Systems
Publication of MXPA04010474A publication Critical patent/MXPA04010474A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
MXPA04010474A 2002-04-25 2003-04-25 Piperazinbenzotiazoles como agentes para el tratamiento de trastornos isquemicos cerebrales o trastornos del sistema nerviosos central. MXPA04010474A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02100417 2002-04-25
PCT/EP2003/004323 WO2003091249A1 (en) 2002-04-25 2003-04-25 Piperazine benzothiazoles as agents for the treatment of cerebral ischemic disorders or cns disorders

Publications (1)

Publication Number Publication Date
MXPA04010474A true MXPA04010474A (es) 2004-12-13

Family

ID=29265991

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04010474A MXPA04010474A (es) 2002-04-25 2003-04-25 Piperazinbenzotiazoles como agentes para el tratamiento de trastornos isquemicos cerebrales o trastornos del sistema nerviosos central.

Country Status (23)

Country Link
US (1) US7314878B2 (sr)
EP (1) EP1501828B1 (sr)
JP (1) JP4523289B2 (sr)
KR (1) KR100948469B1 (sr)
CN (1) CN1310911C (sr)
AT (1) ATE383356T1 (sr)
AU (1) AU2003233067B2 (sr)
BR (1) BRPI0309594A8 (sr)
CA (1) CA2481763C (sr)
CY (1) CY1107204T1 (sr)
DE (1) DE60318567T2 (sr)
DK (1) DK1501828T3 (sr)
EA (1) EA009682B1 (sr)
ES (1) ES2297165T3 (sr)
HK (1) HK1075664A1 (sr)
IL (2) IL164796A (sr)
MX (1) MXPA04010474A (sr)
PT (1) PT1501828E (sr)
RS (1) RS51407B (sr)
SI (1) SI1501828T1 (sr)
UA (1) UA78035C2 (sr)
WO (1) WO2003091249A1 (sr)
ZA (1) ZA200408023B (sr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4523289B2 (ja) 2002-04-25 2010-08-11 メルク セローノ ソシエテ アノニム 脳虚血障害又はｃｎｓ障害の処置のための薬剤としてのピペラジンベンゾチアゾール
ATE378047T1 (de) * 2003-09-12 2007-11-15 Serono Lab Benzothiazol-derivate zur behandlung von diabetes
WO2005118543A1 (ja) * 2004-06-03 2005-12-15 Ono Pharmaceutical Co., Ltd. キナーゼ阻害薬およびその用途
US7838522B2 (en) 2004-11-17 2010-11-23 Ares Trading S.A. Benzothiazole formulations and use thereof
EA011614B1 (ru) * 2004-11-17 2009-04-28 Арес Трейдинг С.А. Препараты бензотиазола и их применение
BRPI0613042A2 (pt) 2005-07-15 2010-12-14 Serono Lab inibidores de jnk para o tratamento de endometriose
KR20080044836A (ko) 2005-07-15 2008-05-21 라보라뚜와르 세로노 에스. 에이. 자궁내막증 치료용 ｊｎｋ 억제제
EP2137173A2 (en) * 2007-04-17 2009-12-30 Laboratoires Serono SA Process for the preparation of piperazine benzothiazoles
WO2009138340A1 (en) * 2008-05-16 2009-11-19 F. Hoffmann-La Roche Ag Inhibitors of jnk
RU2572247C2 (ru) * 2010-06-04 2016-01-10 Ф. Хоффманн-Ля Рош Аг Производные 2-амино-пиримидина в качестве ингибиторов jnk
US8471027B2 (en) * 2011-04-06 2013-06-25 Hoffmann-La Roche Inc. Adamantyl compounds
WO2014114186A1 (zh) * 2013-01-24 2014-07-31 山东亨利医药科技有限责任公司 Jnk抑制剂

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4153574B2 (ja) * 1997-09-10 2008-09-24 トーアエイヨー株式会社 新規なピペリジン誘導体、その製造法およびそれを含有する循環器官用剤
EP1110957A1 (en) * 1999-12-24 2001-06-27 Applied Research Systems ARS Holding N.V. Benzazole derivatives and their use as JNK modulators
EP1193256A1 (en) * 2000-09-27 2002-04-03 Applied Research Systems ARS Holding N.V. Pharmaceutically active benzsulfonamide derivatives as inhibitors of JNK proteins
JP4523289B2 (ja) 2002-04-25 2010-08-11 メルク セローノ ソシエテ アノニム 脳虚血障害又はｃｎｓ障害の処置のための薬剤としてのピペラジンベンゾチアゾール

Also Published As

Publication number Publication date
BRPI0309594A2 (pt) 2016-11-16
EP1501828A1 (en) 2005-02-02
EA200401423A1 (ru) 2005-04-28
ATE383356T1 (de) 2008-01-15
HK1075664A1 (en) 2005-12-23
ES2297165T3 (es) 2008-05-01
EP1501828B1 (en) 2008-01-09
RS92804A (en) 2006-12-15
PT1501828E (pt) 2008-02-11
JP4523289B2 (ja) 2010-08-11
IL164796A0 (en) 2005-12-18
RS51407B (sr) 2011-02-28
SI1501828T1 (sl) 2008-04-30
BRPI0309594A8 (pt) 2017-04-11
CN1310911C (zh) 2007-04-18
DE60318567T2 (de) 2009-02-19
ZA200408023B (en) 2005-11-30
EA009682B1 (ru) 2008-02-28
IL164796A (en) 2013-02-28
CA2481763C (en) 2011-06-14
WO2003091249A1 (en) 2003-11-06
AU2003233067B2 (en) 2009-01-08
AU2003233067A1 (en) 2003-11-10
UA78035C2 (en) 2007-02-15
CN1662528A (zh) 2005-08-31
CA2481763A1 (en) 2003-11-06
DK1501828T3 (da) 2008-03-10
JP2006504631A (ja) 2006-02-09
KR100948469B1 (ko) 2010-03-17
US7314878B2 (en) 2008-01-01
DE60318567D1 (de) 2008-02-21
KR20040104572A (ko) 2004-12-10
US20050261304A1 (en) 2005-11-24
CY1107204T1 (el) 2012-11-21

Similar Documents

Publication Publication Date Title
US20200157082A1 (en) Phenyl indole allosteric inhibitors of p97 atpase
AU2010212339B2 (en) Composition comprising a JNK inhibitor and cyclosporin
TWI235752B (en) Inhibitors of c-JUN N-terminal kinases (JNK) and other protein kinases
JP4966958B2 (ja) カリウムチャネル調節剤及び医療における使用
US7741479B2 (en) Urea inhibitors of MAP kinases
CN100415740C (zh) 嘧啶化合物
ES2316546T3 (es) 2-arilamino-pirimidinas para el tratamiento de trastornos asociados a gsk3.
RU2559895C2 (ru) Азотосодержащие производные гетероарилов
CN101023079B (zh) 用于治疗癌症的取代的乙内酰脲类化合物
US20100331315A1 (en) Rhodanines and related heterocycles as kinase inhibitors
US20090192307A1 (en) Inhibitors of protein kinases
ES2399101T3 (es) Derivados de tiazol y uso de los mismos
MXPA04010474A (es) Piperazinbenzotiazoles como agentes para el tratamiento de trastornos isquemicos cerebrales o trastornos del sistema nerviosos central.
CN108929312A (zh) 具有cdk或hdac抑制活性的新型苯并杂环联嘧啶抑制剂
CN106831780A (zh) 具有cdk4/6和hdac抑制活性的新型杂环衍生物
IL171708A (en) History of pyridinyl acetonitrile for use in the preparation of certain new drugs and their preparation
CN106336412A (zh) 作为cdk4/6抑制剂的2-(n-氧化芳环-2基氨基)-吡咯并嘧啶及嘌呤类化合物
MXPA06011575A (en) Composition comprising a jnk inhibitor and cyclosporin

Legal Events

Date Code Title Description
FG Grant or registration
GB Transfer or rights